Thromboxane B2 (TXB2)

Thromboxane B2 is a metabolite of thromboxane A2 which is known to be highly unstable under physiological conditions. Thromboxane B2 is recognized as a valuable substance for study of a variety of biochemical processes as well as important synthetic precursor to thromboxane A2.Several syntheses of thromboxane B2 have been completed, either in racemic form or deriving the stereocenters from a chiral pool. The Burke group is currently endeavoring to complete the total synthesis of thromboxane B2. Thromboxane B2 is an inactive metabolite/product of thromboxane A2. It is almost completely cleared in the urine.It itself is not involved in platelet activation and aggregation in case of a wound, but its precursor, thromboxane A2, is. Thromboxane A2 synthesis is the target of the drug aspirin, which inhibits the COX-1 enzyme (the source of thromboxane A2 in platelets).